학술논문
Treatment of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis: A position statement from the Thoracic Society of Australia and New Zealand 2023 revision.
Document Type
Article
Author
Mackintosh, John A.; Keir, Gregory; Troy, Lauren K.; Holland, Anne E.; Grainge, Christopher; Chambers, Daniel C.; Sandford, Debra; Jo, Helen E.; Glaspole, Ian; Wilsher, Margaret; Goh, Nicole S. L.; Reynolds, Paul N.; Chapman, Sally; Mutsaers, Steven E.; de Boer, Sally; Webster, Susanne; Moodley, Yuben; Corte, Tamera J.
Source
Subject
*PULMONARY fibrosis
*INTERSTITIAL lung diseases
*DISEASE progression
*IDIOPATHIC pulmonary fibrosis
*
*
*
Language
ISSN
1323-7799
Abstract
Idiopathic pulmonary fibrosis (IPF) is a progressive disease leading to significant morbidity and mortality. In 2017 the Thoracic Society of Australia and New Zealand (TSANZ) and Lung Foundation Australia (LFA) published a position statement on the treatment of IPF. Since that time, subsidized anti‐fibrotic therapy in the form of pirfenidone and nintedanib is now available in both Australia and New Zealand. More recently, evidence has been published in support of nintedanib for non‐IPF progressive pulmonary fibrosis (PPF). Additionally, there have been numerous publications relating to the non‐pharmacologic management of IPF and PPF. This 2023 update to the position statement for treatment of IPF summarizes developments since 2017 and reaffirms the importance of a multi‐faceted approach to the management of IPF and progressive pulmonary fibrosis. [ABSTRACT FROM AUTHOR]